Kyle Doolan

TL;DR: In this paper, the critical residues in the receptor-binding domain (RBD) used by multiple neutralizing antibodies and cocktails were compared and identified a combination of two antibodies CoV2-06 and CoV 2-14 for preventing SARS-CoV-2 escape.

TL;DR: The original version of this Article contained an error in the Acknowledgements, which incorrectly listed the NIH grant ‘AI142759’.

TL;DR: The exquisite specificity of CLDN6 antibodies makes them amenable to use as the tumor-targeting arm of bispecific T-Cell Engagers, and suggests their potential to address the need for potent therapeutic modalities for ovarian and other cancers without compromising patient safety.

TL;DR: Sanchez et al. as discussed by the authors developed bispecific antibodies with the ability to potently kill CLDN18.2-positive or GPRC5D-positive cells, which are novel oncology targets with no clinically approved therapies against them.

TL;DR: Screnci et al. as mentioned in this paper developed an antibody discovery platform (MPS) that specifically addresses each of these challenges through use of advanced immunization techniques and evolutionarily divergent host species (chickens).